Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Fuchs Endothelial Corneal Dystrophy (FECD) Market Snapshot (2023 to 2033)

The global Fuchs endothelial corneal dystrophy (FECD) market garnered a market value of US$ 180 Billion in 2023 and is expected to accumulate a market value of US$ 370 Billion by registering a CAGR of 7.5% in the forecast period 2023-2033. The expanding worldwide aging population, as well as increased awareness of eye illnesses and corneal donation, is likely to boost the market. Furthermore, increased research interest in cellular treatment techniques is expected to generate significant potential for the Industry in the coming years.

The increased incidence of diabetes throughout the world will be a primary driver, resulting in an increase in the market's growth rate. According to the American Optometric Association, approximately 7 million people in the United States have undiagnosed diabetes, with 12,000 to 24,000 people losing their sight each year. Diabetic retinopathy is the leading cause of blindness in the United States today. Diabetic individuals must get a dilated eye exam once a year. By keeping a watch out for retinal anomalies, diabetic issues such as blindness and other consequences can be prevented.

In addition, the occurrence of different diseases such as cataracts, glaucoma, and age-related macular degeneration will drive market expansion. The growing healthcare spending, which aids in the improvement of its infrastructure, is a crucial element driving the growth rate of the market. Furthermore, numerous government organizations intend to improve healthcare infrastructure by boosting financing, which would have an impact on market dynamics.

Data Points Key Statistics
Expected Market Value (2023) US$ 180 Billion
Anticipated Forecast Value (2033) US$ 370 Billion
Projected Growth Rate (2023 to 2033) 7.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Fuchs Endothelial Corneal Dystrophy (FECD) Demand Analysis (2017 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for Fuchs Endothelial Corneal Dystrophy (FECD) is projected to increase at a CAGR of 7.5% during the forecast period between 2023 and 2033, reaching a total of US$ 370 Billion in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6%.

The growing elderly population is expected to boost the market's growth rate. According to the World Ageing 2020 projection, there will be 727 million individuals aged 65 and over in 2020. This population is predicted to reach 1.5 billion by 2050. The proportion of the population aged 65 and older is expected to climb from 9.3% in 2020 to around 16.0% in 2050. The geriatric population is predicted to expand, and this group will require housing.

Furthermore, the growing number of government activities to raise awareness and change people's sedentary lifestyles will result in the rise of the market. Along with this, increased disposable income and expanding government-friendly programs would boost the market’s growth. The market's expansion is being propelled by an increase in the number of Research and Development activities. This would create advantageous prospects for the expansion of the market. Novel entrants are concentrating their efforts on developing new steroid-based formulations to treat dry eye syndrome (DES), which is also a key driving factor in the market.

Which are Some Prominent Drivers of Fuchs Endothelial Corneal Dystrophy (FECD) Market?

Expanding Worldwide Ageing Population to Improve Maintenance and Performance

The expanding worldwide ageing population, as well as increased awareness of eye illnesses and corneal donation, are likely to boost the market. Population growth and ageing are likely to drive up demand for eye care in the coming years. With the world's ageing population, the demand for corneal transplantation is expected to climb dramatically throughout the anticipated period.

Furthermore, researchers throughout the world are studying and developing novel technologies to guarantee the prompt treatment of individuals with Fuchs endothelial corneal dystrophy (FECD). Rising cellular therapy research activity is expected to generate significant prospects for the global market in the coming years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which are the Trough Areas faced by the Fuchs Endothelial Corneal Dystrophy (FECD) Market?

Dangers Associated with Surgical Intervention to Slow Down the Market Growth

The dangers associated with surgical intervention, as well as a scarcity of donor grafts, may have an impact on market growth.

Region-Wise Insights

How will Fuchs Endothelial Corneal Dystrophy (FECD) Market Demand progress in the Asia Pacific?

Progressive Acceptance of Upgraded Technology to Widen Profit Margins

Asian nations are predicted to develop the quickest due to rising awareness, enhanced personal care and cleanliness, increased diagnostic rates, progressive acceptance of upgraded technology, rising disposable income, and burgeoning healthcare infrastructures. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.

How attractive are Growth Prospects for Fuchs Endothelial Corneal Dystrophy (FECD) in North America?

Greater Healthcare Knowledge to Accelerate the Market

Because of greater healthcare knowledge, illness incidence, and a high rate of diagnosis, North America was found to have the highest share of the market.

In this multi-screen universe, individuals of all ages may be found. Computer or digital screen usage may result in less blinking, which may add to symptoms of Fuchs Endothelial Corneal Dystrophy (FECD), hence boosting the need for better and more effective Fuchs Endothelial Corneal Dystrophy (FECD) therapies, which is projected to stimulate growth in the North American region analyzed.

Furthermore, the region's expanding elderly population is driving market expansion since they are more susceptible to numerous ocular ailments such as Fuchs Endothelial Corneal Dystrophy (FECD). North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.

How is the European Fuchs Endothelial Corneal Dystrophy (FECD) Market Shaping?

Increased Research and Development to Drive the Market Growth

With increased research and development, Europe is providing the second-highest share of the Fuchs endothelial corneal dystrophy (FECD) market. Europe is the leading market for corneal transplants, and it will continue to grow in the near future due to the availability of various treatment options and prevention strategies, as well as the growing influence of organ donation programs and growing government focus on organ donation policies. Thus, owing to the aforementioned reasons, Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Which is the Most Preferred End User in the Fuchs Endothelial Corneal Dystrophy (FECD)?

The Hospitals Segment to enhance Sales Prospects

The Fuchs Endothelial Corneal Dystrophy (FECD) market is divided into three segments based on end-users: hospitals, ASCS, and others. The hospital's segment accounts for the majority of the worldwide market.

Start-Ups for Fuchs Endothelial Corneal Dystrophy (FECD) Market

Key start-up players in the Fuchs Endothelial Corneal Dystrophy (FECD) are offering new and innovative product lines to consolidate their market presence, these aforementioned start-ups have left no stone unturned. Some specific instances of key Fuchs Endothelial Corneal Dystrophy (FECD) start-ups are as follows:

  • Oculis is a clinical-stage biopharmaceutical business whose purpose is to create revolutionary topical medicines (eye drops) for ophthalmic illnesses in both the back and front of the eye, with the goal of improving patients' sight and lives globally. Our innovative formulation SNP technology represents a technological breakthrough in ocular medicine formulation, particularly for back-of-the-eye disorders presently treated with invasive approaches such as intraocular injections or implants.
  • Nanodropper has created a patient-centered eye drops bottle adapter that reduces the capacity of already enormous eyedrops by more than 60%. This will assist to reduce the expense, waste, and potential negative effects of vision-saving procedures. Nanodropper's products and instructional content assist people in navigating challenges such as vision insurance, and eye doctor appointments, and efficiently deploying their resources. These programs support Nanodropper's aim of empowering people to regain control of their eye health.
  • Azura Ophthalmics is developing the first ophthalmic keratolytic for the treatment of lid margin illnesses such as Meibomian gland dysfunction (MGD), Blepharitis, and Contact Lens Discomfort. Because Meibomian glands in the eyelids are comparable to hair follicles and sebaceous (oil-producing) glands in the skin1, we employ a combination of ophthalmologic and dermatologic approaches to create effective therapies for MGD and associated diseases.

Market Competition

The market for Fuchs Endothelial Corneal Dystrophy (FECD) is moderately competitive. With regard to market share, the industry is currently dominated by a few significant competitors. With the growing senior population and high illness incidence, a few new smaller competitors are projected to enter the industry in the next years.

Key players in the Fuchs endothelial corneal dystrophy market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc, and Presbia Plc.

Recent Developments:

  • In November 2022, Alcon, the worldwide eye care leader devoted to helping people see brilliantly, announced the completion of its purchase of Aerie Pharmaceuticals, Inc. With its expanding portfolio of commercial medicines and development pipeline, Alcon's footprint in the ophthalmic pharmaceutical field is strengthened by this deal.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 180 Billion
Market Value in 2033 US$ 370 Billion
Growth Rate CAGR of 7.5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US Billion and CAGR from 2023-2033
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Treatment
  • Diagnosis
  • End Users
  • Region
Regions Covered
  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Middle East and Africa (MEA)
Key Countries Profiled
  • The US
  • Canada
  • Brazil
  • Mexico
  • BENELUX
  • France
  • Germany
  • Italy
  • Nordics
  • Spain
  • The UK
  • Poland
  • Russia
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
  • Kowa Pharmaceuticals
  • Trefoil Therapeutics
  • Alcon
  • Emmecell
  • Santen
  • AJL Ophthalmic SA
  • Massachusetts Eye and Ear
  • KeraMed, Inc.
  • Presbia Plc
Customization Available Upon Request

Key Segments Profiled in the Fuchs Endothelial Corneal Dystrophy (FECD) Market Industry Survey

By Treatment:

  • Phototherapeutic Keratectomy
  • Amniotic Membrane Transplants
  • Anterior Stromal Puncture
  • Conjunctival Flaps

By Diagnosis:

  • Slit-lamp Examination
  • Molecular Genetic Tests
  • Pachymetry

By End User:

  • Hospitals
  • ASCs
  • Others

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the anticipated growth of the Fuchs Endothelial Corneal Dystrophy (FECD) market until 2033?

FMI projects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to expand at a 7.5% value CAGR by 2033

What is the estimated market value of the Fuchs Endothelial Corneal Dystrophy (FECD) market expected in 2023?

The global Fuchs Endothelial Corneal Dystrophy (FECD) market is estimated at a market value of US$ 180 Billion

What is the estimated market value of Fuchs Endothelial Corneal Dystrophy (FECD) market expected in 2033?

The global Fuchs Endothelial Corneal Dystrophy (FECD) is expected to garner a market value of US$ 370 Billion

Which region is forecast to be the most lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market growth?

As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 7% in the assessment period 2023 to 2033.

Which are some prominent lucrative Fuchs Endothelial Corneal Dystrophy (FECD) manufacturers?

Key players in the Fuchs Endothelial Corneal Dystrophy (FECD) market are Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, Emmecell, Santen, AJL Ophthalmic SA, Massachusetts Eye, and Ear, KeraMed, Inc and Presbia Plc.

What is the expected market share of North America in the lucrative Fuchs Endothelial Corneal Dystrophy (FECD) market?

North America is expected to grow at a CAGR of 7.4% in the assessment period 2023 to 2033.

What is the expected market share of Europe for lucrative Fuchs Endothelial Corneal Dystrophy (FECD)?

Europe is expected to grow at a CAGR of 7.3% in the assessment period 2023 to 2033.

Which type of vehicle is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) in the forecast period 2023 to 2033?

The hospitals segment is expected to hold the largest market share for lucrative Fuchs Endothelial Corneal Dystrophy (FECD) in the forecast period 2023-2033.

Table of Content

1. Executive Summary | Fuchs Endothelial Corneal Dystrophy (FECD) Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Phototherapeutic Keratectomy

        5.3.2. AMillioniotic Membrane Transplants

        5.3.3. Anterior Stromal Puncture

        5.3.4. Conjunctival Flaps

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033

        6.3.1. Slit-lamp Examination

        6.3.2. Molecular Genetic Tests

        6.3.3. Pachymetry

    6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033

        7.3.1. Hospitals

        7.3.2. ASCs

        7.3.3. Others

    7.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. Asia-Pacific

        8.3.6. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. The US

            9.2.1.2. Canada

        9.2.2. By Treatment

        9.2.3. By Diagnosis

        9.2.4. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Treatment

        9.3.3. By Diagnosis

        9.3.4. By End Users

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Treatment

        10.2.3. By Diagnosis

        10.2.4. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Treatment

        10.3.3. By Diagnosis

        10.3.4. By End Users

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Benelux

            11.2.1.2. France

            11.2.1.3. Germany

            11.2.1.4. Italy

            11.2.1.5. Nordic

            11.2.1.6. Spain

            11.2.1.7. The UK

            11.2.1.8. Rest of Western Europe

        11.2.2. By Treatment

        11.2.3. By Diagnosis

        11.2.4. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By Diagnosis

        11.3.4. By End Users

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Rest of Eastern Europe

        12.2.2. By Treatment

        12.2.3. By Diagnosis

        12.2.4. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By Diagnosis

        12.3.4. By End Users

    12.4. Key Takeaways

13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Malaysia

            13.2.1.3. Singapore

            13.2.1.4. Thailand

            13.2.1.5. Australia

            13.2.1.6. New Zealand

            13.2.1.7. Rest of APAC

        13.2.2. By Treatment

        13.2.3. By Diagnosis

        13.2.4. By End Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By Diagnosis

        13.3.4. By End Users

    13.4. Key Takeaways

14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Treatment

        14.2.3. By Diagnosis

        14.2.4. By End Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment

        14.3.3. By Diagnosis

        14.3.4. By End Users

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. The US

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Treatment

            15.1.2.2. By Diagnosis

            15.1.2.3. By End Users

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Treatment

            15.2.2.2. By Diagnosis

            15.2.2.3. By End Users

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Treatment

            15.3.2.2. By Diagnosis

            15.3.2.3. By End Users

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Treatment

            15.4.2.2. By Diagnosis

            15.4.2.3. By End Users

    15.5. Benelux

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Treatment

            15.5.2.2. By Diagnosis

            15.5.2.3. By End Users

    15.6. France

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Treatment

            15.6.2.2. By Diagnosis

            15.6.2.3. By End Users

    15.7. Germany

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Treatment

            15.7.2.2. By Diagnosis

            15.7.2.3. By End Users

    15.8. Italy

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Treatment

            15.8.2.2. By Diagnosis

            15.8.2.3. By End Users

    15.9. Nordic

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Treatment

            15.9.2.2. By Diagnosis

            15.9.2.3. By End Users

    15.10. Spain

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Treatment

            15.10.2.2. By Diagnosis

            15.10.2.3. By End Users

    15.11. The UK

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Treatment

            15.11.2.2. By Diagnosis

            15.11.2.3. By End Users

    15.12. Poland

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Treatment

            15.12.2.2. By Diagnosis

            15.12.2.3. By End Users

    15.13. Russia

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Treatment

            15.13.2.2. By Diagnosis

            15.13.2.3. By End Users

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Treatment

            15.14.2.2. By Diagnosis

            15.14.2.3. By End Users

    15.15. Malaysia

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Treatment

            15.15.2.2. By Diagnosis

            15.15.2.3. By End Users

    15.16. Singapore

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Treatment

            15.16.2.2. By Diagnosis

            15.16.2.3. By End Users

    15.17. Thailand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Treatment

            15.17.2.2. By Diagnosis

            15.17.2.3. By End Users

    15.18. Australia

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Treatment

            15.18.2.2. By Diagnosis

            15.18.2.3. By End Users

    15.19. New Zealand

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Treatment

            15.19.2.2. By Diagnosis

            15.19.2.3. By End Users

    15.20. GCC Countries

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Treatment

            15.20.2.2. By Diagnosis

            15.20.2.3. By End Users

    15.21. South Africa

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Treatment

            15.21.2.2. By Diagnosis

            15.21.2.3. By End Users

    15.22. Israel

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Treatment

            15.22.2.2. By Diagnosis

            15.22.2.3. By End Users

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Treatment

        16.3.3. By Diagnosis

        16.3.4. By End Users

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Kowa Pharmaceuticals

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Trefoil Therapeutics

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Alcon

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Emmecell

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Santen

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. AJL Ophthalmic SA

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Massachusetts Eye and Ear

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Alcon, Inc.

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. KeraMed, Inc.

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Presbia Plc

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Western Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 15: Western Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 16: Western Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: Eastern Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 19: Eastern Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 20: Eastern Europe Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: APAC Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 23: APAC Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 24: APAC Market Value (US$ Million) Forecast by End Users, 2018 to 2033

Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 27: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033

Table 28: MEA Market Value (US$ Million) Forecast by End Users, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End Users, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 17: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 18: Global Market Attractiveness by Diagnosis, 2023 to 2033

Figure 19: Global Market Attractiveness by End Users, 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 37: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 38: North America Market Attractiveness by Diagnosis, 2023 to 2033

Figure 39: North America Market Attractiveness by End Users, 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 57: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Diagnosis, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End Users, 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Western Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Western Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 63: Western Europe Market Value (US$ Million) by End Users, 2023 to 2033

Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Western Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 71: Western Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 74: Western Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 77: Western Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 78: Western Europe Market Attractiveness by Diagnosis, 2023 to 2033

Figure 79: Western Europe Market Attractiveness by End Users, 2023 to 2033

Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: Eastern Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 82: Eastern Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 83: Eastern Europe Market Value (US$ Million) by End Users, 2023 to 2033

Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 97: Eastern Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 98: Eastern Europe Market Attractiveness by Diagnosis, 2023 to 2033

Figure 99: Eastern Europe Market Attractiveness by End Users, 2023 to 2033

Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 101: APAC Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 102: APAC Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 103: APAC Market Value (US$ Million) by End Users, 2023 to 2033

Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: APAC Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 109: APAC Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 110: APAC Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 111: APAC Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 112: APAC Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 113: APAC Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 114: APAC Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 115: APAC Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 116: APAC Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 117: APAC Market Attractiveness by Treatment, 2023 to 2033

Figure 118: APAC Market Attractiveness by Diagnosis, 2023 to 2033

Figure 119: APAC Market Attractiveness by End Users, 2023 to 2033

Figure 120: APAC Market Attractiveness by Country, 2023 to 2033

Figure 121: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 122: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033

Figure 123: MEA Market Value (US$ Million) by End Users, 2023 to 2033

Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 129: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 130: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 131: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033

Figure 132: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033

Figure 133: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033

Figure 134: MEA Market Value (US$ Million) Analysis by End Users, 2018 to 2033

Figure 135: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 136: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 137: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 138: MEA Market Attractiveness by Diagnosis, 2023 to 2033

Figure 139: MEA Market Attractiveness by End Users, 2023 to 2033

Figure 140: MEA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Ophthalmic Eye Drop Market

Published : March 2024

Healthcare

Corneal Ulcer Treatment Market

Published : June 2022

Healthcare

Ophthalmic Lasers Market

Published : June 2022

Explore Healthcare Insights

View Reports

Fuchs Endothelial Corneal Dystrophy (FECD) Market